Robyn Denholm, globally recognized technology leader and Chair of the Board of Directors at Tesla Inc, has officially joined the board of Harrison.ai, the clinician-led healthcare AI company, effective from 1 July. In addition to her role at Tesla, Denholm currently serves as an Operating Partner of Blackbird Ventures.
Denholm, with her vast experience in strategic advisement, governance oversight, and commercialisation in leading international brands, will be a crucial asset to Harrison.ai as it navigates its next growth phase.
“I'm incredibly excited to be joining the Harrison.ai Board, having been a strategic advisor to the organisation for some time now," Denholm states. "I look forward to working with the Board to realise the Harrison.ai mission to scale global healthcare capacity using AI."
Harrison.ai is at the forefront of healthcare AI, developing and implementing AI diagnostic-assist solutions aimed at increasing accuracy and efficiency in the medical field. With a pioneering approach to commercialising AI medical solutions, Harrison.ai is focused on automating key tasks using AI to enhance the care clinicians can provide.
"We are thrilled to announce that Robyn is joining the board of Harrison.ai and we are excited to work with such an experienced global technology leader," says Dr Aengus Tran, CEO and Co-Founder of Harrison.ai. "Robyn believes in our vision and brings a wealth of knowledge that will be invaluable as we look to our next phase of growth."
Harrison.ai’s joint venture with I-MED Radiology Network, Annalise.ai, has successfully launched two flagship products, Annalise Enterprise CTB and Annalise Enterprise CXR. These decision-support solutions, designed for non-contrast CT brain studies and chest X-rays, are among the most comprehensive in the market.
In 2021, a second joint venture was established with Sonic Healthcare, Franklin.ai, aiming to incorporate AI into the realm of pathology.
Dr Tran further states, "Globally, the healthcare industry faces immense pressure and capacity shortages in clinical diagnosis and treatment. AI automation can play a vital role in addressing systemic issues and improving access to care, and we believe Harrison.ai has the opportunity to impact the sector significantly."